英国儿科患者体外光化学疗法治疗情况的一项调查。
A survey of extracorporeal photopheresis treatment in pediatric patients in the United Kingdom.
作者信息
Flinn Aisling M, Macheka Sheba, Slatter Mary, Ewins Anna-Maria, Gibson Brenda, Lawson Sarah, Tailby Anna, Lucchini Giovanna, New Helen, James Beki, Alfred Arun, Scarisbrick Julia, Gennery Andrew R
机构信息
Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation Great North Children's Hospital Newcastle upon Tyne UK.
Haematology/Oncology Department The Royal Hospital for Children Glasgow UK.
出版信息
EJHaem. 2020 Jul 13;1(1):293-296. doi: 10.1002/jha2.58. eCollection 2020 Jul.
Extracorporeal photopheresis (ECP) is a second-line therapy in acute and chronic GVHD and solid organ transplant rejection. We report ECP use in 98 pediatric patients in seven UK centers from 2010 to 2017, the majority treated for aGVHD (73.5%). ECP was safe and well tolerated including in low body weight patients. Most patients were on multiple immunosuppressive therapies prior to ECP; 45.9% were able to reduce or stop immunosuppression with treatment. Complete or partial response was reported in almost 60%. This study supports the need to include ECP treatment data to national transplant databases to provide accurate information regarding service provision, patient outcomes, and safety.
体外光化学疗法（ECP）是急性和慢性移植物抗宿主病（GVHD）以及实体器官移植排斥反应的二线治疗方法。我们报告了2010年至2017年期间英国七个中心98例儿科患者使用ECP的情况，其中大多数患者（73.5%）接受的是急性移植物抗宿主病（aGVHD）治疗。ECP是安全的，耐受性良好，包括低体重患者。大多数患者在接受ECP治疗前接受了多种免疫抑制治疗；45.9%的患者能够通过治疗减少或停止免疫抑制。近60%的患者报告有完全或部分缓解。本研究支持将ECP治疗数据纳入国家移植数据库的必要性，以提供有关服务提供、患者预后和安全性的准确信息。
Zotero 插件